Last updated: February 24, 2026
What is NDC 42192-0329?
NDC 42192-0329 corresponds to Bemarituzumab, a monoclonal antibody designed for targeting FGFR2b in the treatment of gastric and gastroesophageal junction cancers. It is in late-stage clinical development, with no FDA approval as of the latest update.
Market Size and Growth Potential
Current Market Landscape
- Gastric and gastroesophageal cancers affect approximately 1 million new cases worldwide annually.
- Standard treatments include chemotherapy, targeted therapy, and immunotherapy.
- No approved FGFR2b-targeted therapies exist, positioning Bemarituzumab as a potentially first-in-class drug in this niche.
Competitive Environment
| Competitors |
Drugs / Candidates |
Market Position |
| HER2-targeted therapies |
Trastuzumab, Pertuzumab, Tucatinib |
Established for HER2-positive cases |
| PD-1 inhibitors |
Nivolumab, Pembrolizumab |
Growing use in first- and second-line settings |
| FGFR inhibitors |
Erdafitinib (approved for bladder cancer) |
No FGFR2b-specific agents approved |
Market Entry Timing
Expected FDA/EMA approval window: 2025-2026, contingent on successful trial outcomes and regulatory review timelines.
Forecasted Market Penetration
Initial market penetration reflects cautious adoption:
- Year 1: 5%
- Year 2: 15%
- Year 3: 25%
- Year 4: 35% (as clinical data solidifies safety and efficacy profiles)
Geographic Markets
U.S., Europe, and Asia-Pacific represent primary markets, with the U.S. accounting for nearly 40% of gastric cancer treatment sales.
Pricing Strategy and Projections
Current Pricing Benchmarks
| Drug / Therapy |
Average Annual Cost |
Notes |
| Trastuzumab (HER2-positive) |
$70,000–$120,000 |
Varies by indication and duration |
| Nivolumab (PD-1 inhibitor) |
$150,000–$200,000 |
Based on approved indications |
| FGFR inhibitors (unapproved) |
Not established |
Estimated $40,000–$70,000 per year in experimental use |
Assumed Pricing for Bemarituzumab
- Launch price: $100,000–$125,000 annually
- Adjusted for market competition and payer negotiations
- Pricing flexibility based on clinical benefit demonstration
Projected Revenue Estimates
| Year |
Market Share |
Estimated Revenue (USD millions) |
Assumptions |
| 2026 |
5% |
$50–$75 |
Based on initial launch in U.S. and Europe |
| 2027 |
15% |
$200–$300 |
Increases as clinical data confirms efficacy and safety |
| 2028 |
25% |
$400–$600 |
Wider adoption and expanded indications |
| 2029 |
35% |
$700–$1,000 |
Peak market penetration prior to competing agents |
Cost of Goods Sold (COGS) and Margins
- COGS estimated at 20–30% of list price
- Gross margins projected above 70% as commercialization scales
Risks and Barriers
- Clinical trial failure or delayed approval
- Competition from new entrants and existing therapies
- Payer resistance to high-cost biologics
- Manufacturing scalability and quality control
Key Regulatory Considerations
- FDA breakthrough therapy designation granted (if applicable), fast-tracking approval
- EMA and other regulatory body reviews expected within 6–12 months of submission
- Post-marketing surveillance required to confirm safety profile
Summary
NDC 42192-0329 (Bemarituzumab) has the potential to enter a niche market with high unmet need. Its success depends on clinical outcomes, regulatory approval, and competitive dynamics. Pricing will likely align with existing biologics, around $100,000 per year, with revenue reaching approximately $700 million annually by 2029 if adoption progresses as projected.
Key Takeaways
- Bemarituzumab is a first-in-class FGFR2b-targeted therapy for gastric cancers.
- Market entry is expected around 2025–2026, with significant growth potential.
- Price projections center around $100,000 per year, with potential revenues approaching $1 billion annually.
- Market risks include regulatory hurdles and payer resistance.
- Competitive landscape remains limited but evolving with other FGFR and immunotherapy agents.
FAQs
1. What are the main advantages of Bemarituzumab over existing therapies?
It targets FGFR2b, a driver mutation in a subset of gastric cancers, potentially offering superior efficacy and safety in this population compared to standard chemotherapy.
2. When is FDA approval expected for NDC 42192-0329?
Likely between 2025 and 2026, pending successful trial results and regulatory review.
3. How does pricing compare to other biologics in oncology?
It aligns with similar therapies such as trastuzumab and nivolumab, ranging from $70,000 to $200,000 annually.
4. What are the key markets for Bemarituzumab?
United States, Europe, and Asia-Pacific. The U.S. accounts for approximately 40% of gastric cancer therapy revenues.
5. What is the primary clinical development risk?
Failure to demonstrate enough efficacy or safety in late-stage trials can result in denial or delay of approval.
References
[1] Global Cancer Statistics. (2022). American Cancer Society.
[2] Market Research Future. (2023). Oncology biologics market analysis.
[3] FDA Drug Approvals. (2022). Oncology pipeline updates.
[4] IMS Health. (2023). Oncology drug pricing and reimbursement data.
[5] ClinicalTrials.gov. (2023). Bemarituzumab studies.
